Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuroendocrine tumour16.24.01.009; 05.08.01.0130.000093%Not Available
Meningorrhagia24.07.04.030; 12.01.10.016; 17.08.01.0560.000233%Not Available
Non-alcoholic steatohepatitis14.08.04.024; 09.01.07.0350.000140%Not Available
Intervertebral disc space narrowing15.10.01.0070.000186%Not Available
Palatal oedema07.05.04.0080.000513%Not Available
Cell death14.11.02.005; 08.03.03.0030.000093%Not Available
Gastrointestinal oedema07.11.01.0120.000093%Not Available
Hypertensive emergency24.08.01.0040.000233%Not Available
Sopor19.02.04.002; 17.02.04.0210.000559%Not Available
Placental infarction24.04.12.001; 18.05.02.0050.000093%Not Available
Enlarged uvula07.05.01.0150.000140%Not Available
Stress urinary incontinence20.02.02.0220.000140%Not Available
Cerebral calcification17.11.01.0120.000186%Not Available
Frontotemporal dementia17.03.01.007; 19.20.02.0080.000093%Not Available
Herbal interaction08.06.03.0050.000186%Not Available
Prerenal failure20.01.03.022; 24.06.02.0250.000093%Not Available
Necrotising myositis15.05.05.0160.000093%Not Available
Internal haemorrhage24.07.01.0720.000093%Not Available
Thunderclap headache17.14.01.0180.000233%Not Available
End stage renal disease20.01.03.0190.000373%Not Available
Intracranial mass17.11.01.0170.000093%Not Available
Dilated cardiomyopathy02.04.01.0170.000093%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.038--Not Available
Hypoglycaemia unawareness05.06.03.012; 14.06.03.0120.000186%Not Available
Idiopathic angioedema10.01.05.023; 23.04.01.0230.000140%Not Available
Illness08.01.03.091--Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000186%Not Available
Myalgia intercostal15.05.02.0050.000140%Not Available
Neonatal respiratory distress22.11.02.015; 18.04.10.0040.000233%Not Available
Obstructive pancreatitis09.02.02.006; 07.18.01.0130.000233%Not Available
The 22th Page    First    Pre   22 23    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene